ATE388939T1 - N-((piperazinyl)hetaryl)arylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor - Google Patents

N-((piperazinyl)hetaryl)arylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor

Info

Publication number
ATE388939T1
ATE388939T1 AT04726985T AT04726985T ATE388939T1 AT E388939 T1 ATE388939 T1 AT E388939T1 AT 04726985 T AT04726985 T AT 04726985T AT 04726985 T AT04726985 T AT 04726985T AT E388939 T1 ATE388939 T1 AT E388939T1
Authority
AT
Austria
Prior art keywords
alkyl
cycloalkyl
hetaryl
piperazinyl
haloalkyl
Prior art date
Application number
AT04726985T
Other languages
English (en)
Inventor
Wilfried Braje
Andreas Haupt
Wilfried Lubisch
Roland Grandel
Karla Drescher
Herve Geneste
Liliane Unger
Daryl Sauer
Sean Turner
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of ATE388939T1 publication Critical patent/ATE388939T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04726985T 2003-04-14 2004-04-13 N-((piperazinyl)hetaryl)arylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor ATE388939T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/413,233 US20040204422A1 (en) 2003-04-14 2003-04-14 N-[(Piperazinyl)hetaryl]arylsulfonamide compounds

Publications (1)

Publication Number Publication Date
ATE388939T1 true ATE388939T1 (de) 2008-03-15

Family

ID=33131380

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04726985T ATE388939T1 (de) 2003-04-14 2004-04-13 N-((piperazinyl)hetaryl)arylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor

Country Status (17)

Country Link
US (3) US20040204422A1 (de)
EP (1) EP1613596B1 (de)
JP (1) JP4864694B2 (de)
KR (1) KR101124911B1 (de)
CN (1) CN1805937B (de)
AT (1) ATE388939T1 (de)
AU (1) AU2004228354B2 (de)
BR (1) BRPI0409374A (de)
CA (1) CA2522319C (de)
DE (1) DE602004012400T2 (de)
ES (1) ES2303065T3 (de)
IL (1) IL171421A (de)
MX (1) MXPA05010986A (de)
NZ (1) NZ543101A (de)
PL (1) PL1613596T3 (de)
WO (1) WO2004089905A1 (de)
ZA (1) ZA200509122B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
WO2005011654A2 (en) * 2003-07-29 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
GB0412072D0 (en) * 2004-05-28 2004-06-30 Syngenta Participations Ag Chemical compounds
AU2005302514A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Cyclohexyldiamines as selective alpha 1a/1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms
FR2878524B1 (fr) * 2004-12-01 2007-01-19 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine
MX2007006387A (es) * 2004-12-03 2007-06-20 Hoffmann La Roche Derivados de piridina 3-substituidos como antagonistas h3.
BRPI0517032A (pt) * 2004-12-16 2008-09-30 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
US7713978B2 (en) * 2006-03-31 2010-05-11 Nigel Paul King Compounds
CA2648892A1 (en) * 2006-04-19 2007-10-25 Abbott Gmbh & Co. Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
EP2203426B9 (de) * 2007-10-31 2013-02-13 Abbott GmbH & Co. KG Benzensulfonamid-verbindungen zur behandlung von erkrankungen, die auf dopamin-d3-rezeptormodulation ansprechen
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
WO2010040274A1 (zh) 2008-10-10 2010-04-15 中国人民解放军军事医学科学院毒物药物研究所 新型多巴胺d3受体配体，其制备方法及其医药用途
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
EP3821947A1 (de) * 2019-11-13 2021-05-19 Libra Therapeutics, Inc. Heterozyklische agonisten von trpml1

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE4425145A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
DE4425146A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
JP4327915B2 (ja) * 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
ID26403A (id) * 1998-04-20 2000-12-21 Basf Ag Amida baru yang tersubstitusi, pembuatan dan penggunaannya
CA2386457A1 (en) * 1999-10-06 2001-04-12 Basf Aktiengesellschaft Inhibitors of the endothelin signalling pathway and .alpha.v.beta.3 integrin receptor antagonists for combination therapy
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
DE10040051A1 (de) * 2000-08-11 2002-02-21 Basf Ag Derivate des 4-(Trifluormethyl)-phenols sowie Derivate des 4-(Trifluormethylphenyl)-2-(tetrahydropyranyl)ethers und Verfahren zu ihre Herstellung
DE10131543A1 (de) 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
GB0211005D0 (en) * 2002-05-15 2002-06-26 Ipwireless Inc System,transmitter,receiver and method for communication power control
WO2004058265A1 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors
DE10304870A1 (de) * 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
EP1592690A1 (de) * 2003-02-14 2005-11-09 Wyeth Heterocyclyl-3-sulfonylazaindol- oder -azaindazolderivate als 5-hydroxytryptamin-6-liganden
DE10311065A1 (de) * 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
US7320979B2 (en) * 2003-04-14 2008-01-22 Abbott Gmbh & Co. Kg. N-[(piperazinyl)hetaryl]arylsulfonamide compounds
US20050113576A1 (en) * 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
DE10358004A1 (de) * 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
DE102004027358A1 (de) * 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
WO2006040182A1 (en) * 2004-10-14 2006-04-20 Abbott Gmbh & Co. Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
EP1809597B1 (de) * 2004-10-14 2012-01-11 Abbott GmbH & Co. KG Zur behandlung von erkrankungen, die auf eine modulation des dopamin-d3-rezeptors ansprechen, geeignete aminoethylaromatische verbindungen
US8101754B2 (en) * 2004-12-02 2012-01-24 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

Also Published As

Publication number Publication date
KR20060005367A (ko) 2006-01-17
IL171421A (en) 2012-03-29
CN1805937A (zh) 2006-07-19
US20040204422A1 (en) 2004-10-14
US8476275B2 (en) 2013-07-02
PL1613596T3 (pl) 2008-09-30
KR101124911B1 (ko) 2012-03-27
AU2004228354A1 (en) 2004-10-21
ZA200509122B (en) 2007-04-25
CA2522319C (en) 2013-10-15
CN1805937B (zh) 2012-07-11
JP2006522769A (ja) 2006-10-05
NZ543101A (en) 2009-02-28
AU2004228354B2 (en) 2010-04-22
US20110294817A1 (en) 2011-12-01
EP1613596A1 (de) 2006-01-11
WO2004089905A1 (en) 2004-10-21
BRPI0409374A (pt) 2006-04-25
ES2303065T3 (es) 2008-08-01
EP1613596B1 (de) 2008-03-12
MXPA05010986A (es) 2005-12-15
US20070054918A1 (en) 2007-03-08
DE602004012400D1 (de) 2008-04-24
DE602004012400T2 (de) 2009-04-02
CA2522319A1 (en) 2004-10-21
JP4864694B2 (ja) 2012-02-01

Similar Documents

Publication Publication Date Title
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
ATE388939T1 (de) N-((piperazinyl)hetaryl)arylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
EA201891463A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK)
EA200800815A1 (ru) 2-анилин-4-арилзамещенные тиазольные производные
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
ATE493407T1 (de) 3-(heteroaryloxy)-2-alkyl-1- azabicycloalkylderivate als alpha.7-nachr- liganden zur behandlung von zns-erkrankungen
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
MY156747A (en) Isoxazolo-pyridine derivatives
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
GEP20105053B (en) Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
EA200970598A1 (ru) Замещенные производные гетероарилпиридопиримидона
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
MX2010005753A (es) Derivados de isoxazolo-pirazina.
ATE390415T1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
DE602006010540D1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
EA200701758A1 (ru) Замещённые арильные производные 1,4-пиразина
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
TW200637556A (en) Substituted 5-phenyl pyrimidines I in therapy
DE602006017849D1 (de) 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1613596

Country of ref document: EP